ANIK Anika Therapeutics Inc

Price (delayed)

$39.88

Market cap

$571.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.69

Enterprise value

$496.53M

Sector: Healthcare
Industry: Biotechnology

Highlights

Anika Therapeutics's debt has shrunk by 55% QoQ and by 2.3% YoY
The revenue has grown by 14% YoY and by 2.3% from the previous quarter
The company's EPS has shrunk by 188% YoY
The net income has dropped by 188% year-on-year

Key stats

What are the main financial stats of ANIK
Market
Shares outstanding
14.33M
Market cap
$571.47M
Enterprise value
$496.53M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.08
Price to sales (P/S)
4.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.81
Earnings
Revenue
$130.46M
EBIT
-$28.32M
EBITDA
-$13.33M
Free cash flow
$11.44M
Per share
EPS
-$1.69
Free cash flow per share
$0.8
Book value per share
$19.16
Revenue per share
$9.17
TBVPS
$18.71
Balance sheet
Total assets
$365.61M
Total liabilities
$93.21M
Debt
$20.88M
Equity
$272.4M
Working capital
$140.52M
Liquidity
Debt to equity
0.08
Current ratio
4.81
Quick ratio
3.32
Net debt/EBITDA
5.62
Margins
EBITDA margin
-10.2%
Gross margin
52.9%
Net margin
-18.4%
Operating margin
-43.7%
Efficiency
Return on assets
-5.9%
Return on equity
-8.4%
Return on invested capital
-14.4%
Return on capital employed
-8.6%
Return on sales
-21.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ANIK stock price

How has the Anika Therapeutics stock price performed over time
Intraday
-0.82%
1 week
-1.29%
1 month
9.41%
1 year
22.93%
YTD
-11.89%
QTD
-2.23%

Financial performance

How have Anika Therapeutics's revenue and profit performed over time
Revenue
$130.46M
Gross profit
$69.03M
Operating income
-$56.99M
Net income
-$23.98M
Gross margin
52.9%
Net margin
-18.4%
The net income has dropped by 188% year-on-year
Anika Therapeutics's net margin has shrunk by 178% YoY
Anika Therapeutics's operating income has plunged by 162% from the previous quarter
Anika Therapeutics's operating margin has plunged by 157% from the previous quarter

Growth

What is Anika Therapeutics's growth rate over time

Valuation

What is Anika Therapeutics stock price valuation
P/E
N/A
P/B
2.08
P/S
4.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.81
The company's EPS has shrunk by 188% YoY
ANIK's price to book (P/B) is 17% more than its last 4 quarters average of 1.8 but 16% less than its 5-year quarterly average of 2.5
ANIK's equity is down by 6% year-on-year and by 4.2% since the previous quarter
ANIK's P/S is 23% below its 5-year quarterly average of 5.7 but 7% above its last 4 quarters average of 4.1
The revenue has grown by 14% YoY and by 2.3% from the previous quarter

Efficiency

How efficient is Anika Therapeutics business performance
Anika Therapeutics's ROE has plunged by 184% YoY
The ROIC has dropped by 183% year-on-year
The company's return on sales has shrunk by 173% YoY
The return on assets has dropped by 168% year-on-year

Dividends

What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIK.

Financial health

How did Anika Therapeutics financials performed over time
Anika Therapeutics's total liabilities has soared by 120% YoY but it has decreased by 29% from the previous quarter
Anika Therapeutics's quick ratio has plunged by 74% YoY and by 30% from the previous quarter
Anika Therapeutics's debt is 92% lower than its equity
Anika Therapeutics's debt has shrunk by 55% QoQ and by 2.3% YoY
The debt to equity has dropped by 50% since the previous quarter but it is up by 14% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.